DrugPatentWatch Database Preview
IMODIUM MULTI-SYMPTOM RELIEF Drug Profile
» See Plans and Pricing
When do Imodium Multi-symptom Relief patents expire, and when can generic versions of Imodium Multi-symptom Relief launch?
Imodium Multi-symptom Relief is a drug marketed by J And J Consumer Inc and is included in two NDAs.
The generic ingredient in IMODIUM MULTI-SYMPTOM RELIEF is loperamide hydrochloride; simethicone. There are eleven drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the loperamide hydrochloride; simethicone profile page.
Summary for IMODIUM MULTI-SYMPTOM RELIEF
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Suppliers / Packagers: | 1 |
| Clinical Trials: | 22 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | IMODIUM MULTI-SYMPTOM RELIEF at DailyMed |
Recent Clinical Trials for IMODIUM MULTI-SYMPTOM RELIEF
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Naia Pharmaceuticals | Phase 1/Phase 2 |
| McNeil AB | Phase 1 |
| Allergan | Phase 2 |
Paragraph IV (Patent) Challenges for IMODIUM MULTI-SYMPTOM RELIEF
| Tradename | Dosage | Ingredient | NDA | Submissiondate |
|---|---|---|---|---|
| IMODIUM MULTI-SYMPTOM RELIEF | TABLET;ORAL | loperamide hydrochloride; simethicone | 021140 | 2004-12-29 |
| IMODIUM MULTI-SYMPTOM RELIEF | TABLET, CHEWABLE;ORAL | loperamide hydrochloride; simethicone | 020606 |
US Patents and Regulatory Information for IMODIUM MULTI-SYMPTOM RELIEF
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET, CHEWABLE;ORAL | 020606-001 | Jun 26, 1996 | DISCN | Yes | No | Start Trial | Start Trial | Start Trial | ||||
| J And J Consumer Inc | IMODIUM MULTI-SYMPTOM RELIEF | loperamide hydrochloride; simethicone | TABLET;ORAL | 021140-001 | Nov 30, 2000 | OTC | Yes | Yes | Start Trial | Start Trial | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IMODIUM MULTI-SYMPTOM RELIEF
International Patents for IMODIUM MULTI-SYMPTOM RELIEF
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Greece | 1002091 | Start Trial |
| European Patent Office | 0571217 | Start Trial |
| European Patent Office | 0428296 | Start Trial |
| Argentina | 013227 | Start Trial |
| Portugal | 891776 | Start Trial |
| Hungary | 9801615 | Start Trial |
| Greece | 930100197 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for IMODIUM MULTI-SYMPTOM RELIEF
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0428296 | 99C0029 | Belgium | Start Trial | PRODUCT NAME: LOPERAMIDUM HYDROCHOLORIDUM SEMITHICONUM; NATL. REGISTRATION NO/DATE: 2 IS 145 F3 19990201; FIRST REGISTRATION: GB PL 00242/0314 19970923 |
| 0428296 | SPC/GB98/013 | United Kingdom | Start Trial | PRODUCT NAME: LOPERAMIDE HYDROCHLORIDE AND SIMETHICONE; REGISTERED: UK 00242/0314 19970923 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
